Mitochondrial target of thiazolidinediones.
Insulin-sensitizing thiazolidinediones exert a pleiotropic pharmacology with therapeutic potential in a number of disease states ranging from metabolic syndrome and diabetes to neurodegeneration and cancer. A growing understanding of their mechanism of action, working from the site of their binding in the mitochondrion, provides insight into the mechanism of action of the insulin sensitizers and the reasons for their pleiotropic pharmacology. This review helps to frame the direction of future work that should be helpful in setting a new direction for the discovery and development of new, more useful therapeutic agents for metabolic disease.
Metabolic Solutions Development Company, Kalamazoo, MI, USA.
J R
JR
Colca
W G
WG
McDonald
R F
RF
Kletzien
D000818:Animals; D004195:Disease Models, Animal; D004330:Drosophila; D055808:Drug Discovery; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000235:genetics; D000078790:Insulin Secretion; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D045162:Thiazolidinediones / Q000494:pharmacology
D007328:Insulin; D045162:Thiazolidinediones
diabetes mellitus; insulin resistance; thiazolidinediones